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A novel approach to complement human immunodeficiency virus type I (HIV-1) integrase (IN)-defective virions has been
identified. The approach involves fusion of a 23-amino-acid stretch to the N-terminus of wild-type IN and coexpression of this
chimera with the IN-defective proviral template in virus producing cells. The 23-amino-acid peptide represents a Vpr
“interactor,” referred to as the the WxxF or WF domain, which apparently leads to docking of the domain along with the fusion
partner onto HIV-1 Vpr, thus permitting virion incorporation of the chimeric protein when expressed, in trans, with other viral
products. Transfection of the WF-IN expression plasmid along with HIV-1 viral clones that produce Vpr, but bear an IN
mutation, results in the release of a proportion of viral particles that are competent for integration. The extent of
complementation was assessed using the MAGI cell assay, where integration of viral DNA results in the eventual appearance
of easily visible multinucleated blue syncytia. The efficiency of dWF-IN (double copy of WF domain) complementation is not
improved markedly by incorporation of a HIV-1 protease cleavage site (PR) between the dWF domain and IN (dWF-PR-IN),
unlike that observed with Vpr fusions to IN. Furthermore, the ability of Vpr-PR-IN and dWF-PR-IN to complement IN-defective
proviral clones, both of which bear an intervening protease cleavage site, appear comparable. Western blotting analyses
using virions isolated through sucrose cushions demonstrate clearly the incorporation of the dWF-IN fusion protein into Vpr
containing HIV-1 particles but not in Vpr-deficient virions. Additional Western blotting analyses indicate that all Vpr-IN and
dWF-IN chimeras, with or without a PR site, are packaged into virions. The efficiency of virion incorporation of Vpr-IN and
dWF-IN chimeras appears approximately comparable by Western blotting analysis. The ability of dWF-IN to complement
IN-defective proviruses with efficiency similar to that of Vpr-PR-IN and dWF-PR-IN indicates that dWF-IN retains the full
complement of functions necessary for integration of proviral DNA and is likely due to the benign nature of this small domain
at the amino-terminus of IN. © 1999 Academic PressKey Words: HIV-1; Vpr; integrase; virions.
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The efficient replication of retroviruses requires inte-
ration of the double-stranded DNA copy of viral RNA
nto chromosomal DNA of the infected host cell (Kulko-
ky and Skalka, 1994; Farnet and Bushman, 1996). Inte-
ration for all retroviruses, including human immunode-
iciency virus type 1 (HIV-1) (La Femina et al., 1992),
epresents the stable incorporation of viral DNA into that
f the host and depends upon the function of the viral-
ncoded enzyme integrase.
Integration occurs in two discrete steps (Goff, 1992).
irst, integrase (IN) removes two nucleotides from the 39
nds of the newly synthesized viral DNA within the cy-
oplasm of the infected host cell (Roth et al., 1989; Brown
t al., 1989). This step is typically referred to as the
rocessing reaction. The processed viral DNA, which is
ontained within a larger nucleoprotein complex in the
nfected cell (Bowerman et al., 1989), is then inserted into
1 To whom reprint requests should be addressed. Fax: (215) 923-
g956. E-mail: kulkosk1@jeflin.tju.edu.
77ost chromosomal DNA. This insertion step, which rep-
esents a trans-esterification event, is referred to as the
oining reaction.
The biochemical mechanisms that underpin IN pro-
essing and joining have been elucidated largely by the
se of simple in vitro assays that require only purified
ecombinant enzyme and short oligodeoxynucleotide du-
lex DNA substrates (Katzman et al., 1989; Craigie et al.,
990; Katz et al., 1990; Engleman et al., 1993). Amino acid
equence alignments for several IN species and exten-
ive mutagenesis of the protein have defined conserved
unctional regions (Engelman et al., 1993), including the
ctive site of the enzyme, which is referred to as the
,D(35)E domain (Kulkosky et al., 1992; Engelman and
raigie, 1992). The recent X-ray crystal structure of the
,D(35)E domain of HIV-1 IN suggests that the design of
ffective active site inhibitors may soon be feasible
Dyda et al., 1994).
The rapid advances in our understanding of IN struc-
ure and function, in conjunction with simple and rapid in
itro activity assays, have provided the basis for a new
eneration of studies directed toward: (1) inhibition of IN
0042-6822/99 $30.00
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78 KULKOSKY ET AL.ctivity (Levy-Mintz et al., 1996) by rational design; (2) the
ddition of various discrete DNA binding domains (Bush-
an 1995; Goulaouic and Chow, 1996; Katz et al., 1996) to
onvert integration into a site-specific process; or (3)
edirection of its mode of delivery into virions (Liu et al.,
997; Fletcher et al., 1997) in order to assess IN’s con-
ribution to virion architecture or to define its possible
nteraction with other virion proteins that may affect the
ynamics of the integration process.
With regard to the last efforts, we have identified a
ovel strategy to deliver IN into virus particles, the mech-
nism of which is independent of the natural mode of
ncorporation that involves protease maturation of the
ag-Pol polypeptide precursor. The approach employs
n in-frame fusion of a 23-amino-acid stretch to the
-terminus of IN. Interestingly, this 23-amino-acid pep-
ide represents a Vpr “interactor” found in uracil DNA
lycosylase (UDG), which is referred to as the WxxF or
F domain (BouHamdan et al., 1998). A double-cassette
f the WF motif, designated dWF, fused to the bacterial
hloramphenicol acetyl transferase (CAT) gene leads to
mport of the chimera into HIV-1 virus particles (BouHam-
an et al., 1998). Previous studies indicate that fusion to
he WF motif double-cassette leads to incorporation of
igher levels of the chimera into viral particles (BouHam-
an et al., 1998). The dWF-IN chimera is incorporated
nto virions, likely by docking to the viral accessory pro-
ein, Vpr, and can restore integration activity to full-length
enomic viral templates that bear a variety of IN muta-
ions. The copy number of chimeric molecules delivered
ppears comparable to the levels of proviral derived IN
;50 to 150 copies) and is likely related to the ability to
e transported by associating with the higher copy num-
er of Vpr molecules that are encapsidated within HIV-1
articles (Cullen, 1998). This strategy for the in trans
elivery of IN into whole virions, which is independent of
he expression of products from the viral genome, could
e useful for assessing rapidly the in vivo effects of IN
utations to further advance structure/function studies
f the protein. The strategy might also be used to define
he critical interactions between IN and other viral pro-
eins that contribute to virion architecture. Finally, this
ode of delivery could also be exploited as a novel
eans to direct protein-based inhibitors into mature
IV-1 particles aimed at reducing or eliminating virion
nfectivity.
RESULTS
yncytia-forming assay to assess dWF-IN
omplementation
Our initial experiments were performed to test directly
hether the 23-amino-acid Vpr interactor peptide, re-
erred to as the dWF domain, could import IN into HIV-1
irions and restore integration to mature particles that
ould otherwise lack this function. This premise was cased on previous studies from our laboratory demon-
trating that the CAT gene product could be delivered
nto HIV-1 virions as a fusion to the dWF motif when the
himera was expressed in trans of an HIV-1 proviral
xpression clone (BouHamdan et al., 1998). In order to
ssess whether the dWF could similarly transport an
IV-1 viral gene product, such as IN, several proviral
xpression constructs were obtained. The key features
f three HIV-1 constructs, which are incapable of inte-
rating HIV-1 DNA after reverse transcription, are shown
n Fig. 1. The first construct tested bears a single muta-
ion, D116N, an IN active site point mutation, and the two
dditional proviral clones bear stop codons within the
oding sequence of IN that result in premature termina-
ion of the protein at amino acid positions 4 and 234.
hese plasmids are required in the complementation
tudies described below. Their use relies on the premise
hat IN is transported into HIV-1 virions by in trans ex-
ression of IN as a fusion to either Vpr or dWF. The
onstructs illustrated in Fig. 1B represent the expression
assettes for the chimeras, which are incorporated into
irus particles. These IN fusions are next shown to be
apable of catalyzing integration of viral DNA.
Figure 2 illustrates the results of a syncytia-forming
ssay from an infection of MAGI cells with three virus-
ontaining supernatants prepared by single or cotrans-
ection of selected expression plasmids described
bove. The approach is based on the expectation that
ells bearing an integrated HIV-1 provirus would, over
ime, produce sufficient levels of the envelope gene
roduct to induce multicellular fusion and Tat to trigger
verexpression of b-galactosidase, which would stain
nfected cells deep blue after exposure to X-gal (Kimpton
nd Emerman, 1992).
As shown in Fig. 2A, MAGI cells infected with virions
earing the IN(D116N) mutation yield, almost exclusively,
nfrequent, single cells that are stained light to medium
lue. In contrast, wild-type NL4-3 virions induce many
arge multinucleated deep blue syncytia, an example of
hich is shown in Fig. 2B. HIV-1 virions derived from
otransfection of 293T cells with pNL4-3/IN(D116N) and
LX-CMV-dWF-PR-IN (Fig. 2C) also are capable of initi-
ting syncytia formation, but to a significantly lesser
xtent, and generally do not involve the fusion of as many
ells as observed with infection of the MAGI cells using
ild-type HIV-1 particles. This seems appropriate since
irions generated by cotransfection are expected to be
apable of only a single round of infection, thereby lim-
ting the overall population of cells capable of participat-
ng in syncytia formation. With regard to overall number,
here were approximately four- to sixfold less syncytia for
omplemented virions versus infection with wild-type
irus depending on the state of the MAGI cells since they
ay elicit a high background of singly stained cells or
onversely be unresponsive to staining even after suc-
essful infection (see Discussion). Nevertheless, these
i
w
d
r
H
I
t
w
c
f
a
s
s
a
f
p
t
d
V
D
r
D
t
i
79dWF MOTIF AND HIV-1 INTEGRASEnitial experiments provided a clear indication that IN
as incorporated into mature HIV-1 particles as an in-
ependently expressed fusion to the dWF domain and
etained those functions required for the integration of
IV-1 DNA.
mport of the dWF-IN chimera is Vpr dependent
Next, we sought to demonstrate the actual presence of
he dWF-IN chimera within virions and also determine
hether delivery of the protein was dependent upon the
FIG. 1. Schematic of HIV-1 proviral DNA constructs and Vpr or dWF
NA is shown (without accessory genes) highlighting the approximat
equired for integration of viral DNA. Below is shown the type of IN mu
,D(35)E domain (1), and two premature IN termination mutants, IN (1-4
hat lack the ability to integrate HIV-1 DNA. PR designates the protease
tself.oexpression of Vpr, as had been shown previously for Iusion of dWxxF to the CAT gene product (BouHamdan et
l., 1998). dWF-IN, which lacks the protease cleavage
ite, was used since this species would exhibit slightly
lower mobility in PAGE and by immunoblotting would
ppear as a band about 2.5 kDa larger than IN derived
rom natural protease processing of the HIV-1 Gag-Pol
olyprotein precursor. As shown in Fig. 3, lane 1, infec-
ion with HIV-1 NL4-3 IN(D116N) alone shows a single
iscrete band at 32 kDa corresponding to IN(D116N).
irions derived from cells cotransfected with NL4-3
era expression plasmids. (A) The simple linear map of HIV-1 proviral
n that encodes IN at the 39 end of the pol domain whose integrity is
in three HIV-1 proviral constructs, D116N, an active site mutant in the
(1-234) (see Engelman et al., 1995). All three plasmids produce virions
ge site that occurs between RNase H and IN and not HIV-1 proteaseIN chim
e regio
tation
) and IN
cleavaN(D116N) and SLX-CMV-dWF-IN reveal the presence of
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80 KULKOSKY ET AL.wo bands, as shown in Fig. 3, lane 2, IN (D116N) iden-
ical to that observed in lane 1, and also a less intense
pecies slightly above IN(D116N) whose size is consis-
ent with that predicted for dWF-IN. This protein is not
resent in virions derived from cotransfection of NL4-3
VPR and SLX-CMV-dWF-IN (lane 3), even though IN
erived from the proviral template at 32 kDa is nearly of
qual intensity relative to that observed in lane 2. Anal-
sis of particles from cotransfection of NL4-3 and SLX-
MV-dWF-IN, in lane 4, shows two bands of almost equal
ntensity, consistent with packaging of IN from natural
ag-Pol polyprotein processing and the slower migrating
WF-IN. This suggests that packaging of the dWF-IN
himera may be more efficient within wild-type particles
han within particles bearing Vpr or IN mutations. This
FIG. 2. dWF-PR-IN restores integration activity to HIV-1 IN (D116N)-d
MAGI) cells were infected with virions derived from transfection of 293
right) pNL4-3/IN (D116N) DNA and SLX-CMV-dWF-PR-IN DNA. Cells w
FIG. 3. Western blotting analysis of dWF-IN import into HIV-1 Vpr1
nd Vpr2 virions. 293T cells were transfected with: (1) pNL4-3/IN
D116N) alone; (2) pNL4-3/IN (D116N) 1 SLX-CMV-dWF-IN; (3) pNL4-3
DVpr) 1 SLX-CMV-dWF-IN; and (4) pNL4-3 1 SLX-CMV-dWF-IN. After
ransfection, supernatants from cells were harvested and virions were
oncentrated by ultracentrifugation through a 20% sucrose cushion.
irions were then subjected to PAGE/Western blot analysis using a
olyclonal antiserum against HIV-1 IN. The slightly slower speciesaisible above IN at 32 kDa represents the dWF-IN chimeric protein.ight be expected as aberrant infectivity and morphol-
gy have been observed previously for virions that bear
variety of IN mutations (Engleman et al., 1995). It is also
orth noting that the copy number of the chimeric protein
mported into virions is dependent upon the ratio during
TABLE 1
Analysis of VPR-PR-IN, dWF-IN, and dWF-PR-IN Complemented
IN-Defective HIV-1 Particles
HIV-1 Proviral template
and IN fusion complement
No. of blue
syncytia % WT
D116N only 14 6.9
D116N 1 dWF-IN 42 20.8
D116N 1 dWF-PR-IN 52 25.7
D116N 1 Vpr-PR-IN 43 21.3
IN (1-234) only 13 6.4
IN (1-234) 1 dWF-PR-IN 44 21.7
NL4-3 (WT) 202 100.0
Note. Three HIV-1 expression plasmids (strain NL4-3), wild-type and
wo bearing IN mutations, were transfected into 293T cells alone or
otransfected with three expression plasmids bearing wild-type IN
used to Vpr or the dWF domain. PR represents the natural HIV-1
rotease RT-IN cleavage site included between the fusion with Vpr and
WF. Viral supernatants derived from transfection 3 days later were
ormalized for p24 antigen by ELISA (each ;10 ng/ml) before applica-
ion to MAGI reporter cells in 60 3 15 plastic culture dishes. Only deep
lue syncytia were counted and the numbers above represent the
virions as assessed by a syncytia-forming assay. HeLa CD41; b-gal
with (left). pNL4-3/IN (D116N) DNA alone; (middle). pNL4-3 DNA alone;
ined for b-galactosidase activity 3 days after infection.efective
T cellsverage from duplicate plates. WT, wild-type.
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81dWF MOTIF AND HIV-1 INTEGRASEransfection of the chimera expression plasmid relative
o that of the proviral clone (Liu et al., 1997; Fletcher et al.,
997). In the comparisons of the complementation as-
ays described below this molar ratio was generally two-
o threefold higher with the Vpr or dWF-IN expression
lasmids during transfections of the 293T producer cells
o generate virus particles.
omparison of the complementation efficiencies of
IV-1 IN-deficient proviruses by Vpr-IN and dWF-IN
himera expression plasmids
The relative efficiencies of the Vpr-IN and WxxF-IN
himera expression plasmids were tested in the MAGI
ssay for their ability to complement three IN mutant
roviral clones. As shown in Fig. 1, the three integration-
eficient proviruses included an IN active-site point mu-
ant (IN D116N) and two premature IN termination mu-
ants (IN 1-4 and IN 1-234). HIV-1 IN is normally 288
mino acids in length.
FIG. 4. Syncytia-forming assay illustrating complementation of pNL4-3
nfected with virions derived from transfection of 293T cells with th
-galactosidase expression 2.5 days later and representative fields ofBased on the formation of deep blue syncytia, VPR- MR-IN, dWF-IN, and dWF-PR-IN appeared to complement
ll three mutants with equivalent efficiencies. As shown
n Table 1, the noncomplemented IN (D116N) provirus
ielded only a few “syncytia,” approximately fourfold less
han its complemented counterparts. These multiple blue
ells scored as syncytia likely represent the background
ue to the division of a singly stained cell yielding a
our-cell figure but nonetheless were included in the
ounting procedure. Figures 2 and 4 illustrate the distinct
orphology of the deeply stained syncytia derived from
nfection with complemented virions. As shown in Table
, virus from HIV-1 IN (D116N) cotransfected with IN
himera expression plasmids yielded syncytia that were
pproximately fivefold less in number than infection with
ild-type HIV-1. This result concurs with that reported for
omplementation by VPR-PR-IN using different methods
f analysis where the complemented virus was approx-
mately 20–25% that of wild-type HIV-1 infection (Liu et
l., 1997; Fletcher et al., 1997). This suggests that the
34) by various Vpr-IN or dWF-IN expression plasmids. MAGI cells were
templates as indicated above each panel. Cells were stained for
d cells are shown./IN (1-2
e DNAAGI assay based on syncytia formation was a reliable
m
t
I
p
a
a
n
s
e
s
T
c
s
c
t
I
r
l
y
p
l
c
l
I
k
q
p
t
P
p
T
s
a
m
d
f
t
(
w
H
e
n
(
w
t
e
s
g
p
H
t
a
i
s
f
o
1
o
i
e
t
I
i
d
d
R
I
p
c
1
m
n
H
o
3
p
g
t
p
82 KULKOSKY ET AL.eans of quantitating the relative extent of complemen-
ation.
In Table 2, the relative complementation efficiencies of
N derived from cotransfection of IN chimera expression
lasmids with integration-deficient proviruses [IN (1-4)
nd IN (1-234)] were determined. The results from this
nalysis were similar to those described above. The
umbers of syncytia scored were fewer owing to the
maller culture dish format but nevertheless were almost
qual in number for VPR-PR-IN, dWF-IN, and dWF-IN,
uggesting equivalent levels of complementation.
he relative level of IN-chimera incorporation into
omplemented HIV-1 virions
To be further assured that the MAGI assay based on
yncytia formation demonstrated complementation effi-
iency with reasonable accuracy, the level of incorpora-
ion into virions for the various IN fusions was assessed.
n Fig. 5A, a comparison of VPR-IN and dWF-IN incorpo-
ation into HIV-1 IN (D116N) particles is illustrated. In
ane 1, VPR-IN, which lacks a protease cleavage site,
ields a band of ;46.5 kDa that migrates above the
roviral-derived 32-kDa IN (D116N). As shown in this
ane, the quantity of these two species within the su-
rose cushion-derived virus particles appears equal. In
ane 2, the wide band likely represents a doublet of both
N (D116N) below and dWF-IN above that is about 2.5
Da larger. The 10–20% Tris–HCl gel system was inade-
uate for the separation of these two species despite
rolonged electrophoresis. Figure 5B illustrates separa-
ion of IN(D116N) and dWF-IN using 10–20% Tris–tricine
AGE. As shown in lane 2, dWF-IN appears to be incor-
orated at approximately the same level as IN(D116N).
hese results indicate that the Vpr and dWF chimeric IN
pecies can be incorporated into HIV-1 particles typically
t levels similar to IN derived from the provirus. Further-
TABLE 2
Analysis of VPR-PR-IN, dWF-IN, and dWF-PR-IN Complementation
of IN Deletion Mutant HIV-1 Particles
HIV-1 Proviral template
and IN fusion complement
No. of blue
syncytia
IN (1-4) only 2
IN (1-4) 1 dWF-IN 10
IN (1-4) 1 dWF-PR-IN 18
IN (1-4) 1 Vpr-PR-IN 16
IN (1-234) only 3
IN (1-234) 1 dWF-IN 14
IN (1-234) 1 dWF-PR-IN 20
IN (1-234) 1 Vpr-PR-IN 18
Note. Experiments were performed as described in Table 1, except
hat MAGI cells were stained for b-galactosidase expression 2.5 days
ostinfection with equilibrated viral supernatants.ore, the carrier proteins Vpr and dWF do not appear to giffer dramatically in the efficiency of transporting their
usion partner into virions.
DISCUSSION
The WxxF motif was discovered initially as an interac-
or with Vpr using peptide phage display methodology
BouHamdan et al., 1998). The occurrence of this motif
ithin cellular proteins that are known to associate with
IV-1 Vpr such as uracil DNA glycosylase (BouHamdan
t al., 1996) and TFIIB (Agostini et al., 1996) fortifies the
otion that the diverse effects Vpr can have upon cells
Emerman, 1996) may be related to its ability to interact
ith additional, multiple cellular targets that also bear
he WxxF motif (BouHamdan et al., 1998). In an effort to
xploit the interaction of the WxxF motif with Vpr, it was
hown that a dimer of the WxxF motif fused to the CAT
ene resulted in efficient incorporation of the chimeric
rotein into sucrose gradient purified HIV-1 virions (Bou-
amdan et al., 1998). Additional studies comparing the
ransport of the CAT gene product into virus particles as
fusion to Vpr or dWF revealed comparable levels of
ncorporation, based upon the quantitation of virion-as-
ociated CAT activity. As expected, transport of CAT via
usion to the dWF motif was dependent upon expression
f Vpr from the proviral template (BouHamdan et al.,
998).
The initial and elegant efforts of incorporating a variety
f proteins as fusions to Vpr provided the first means to
ntroduce proteins into HIV-1 particles at reasonable lev-
ls that were not dependent upon direct expression from
he proviral clone (Liu et al., 1997; Fletcher et al., 1997).
nterestingly, the ability of the Vpr fusion partner to man-
fest its expected activity varied, however. For instance,
irect fusion of HIV-1 reverse transcriptase (RT) to Vpr
oes not hamper the chimera’s ability to complement
T-deficient virus, unlike a similar fusion context to HIV-1
N. In this case, introduction of an intervening HIV-1
rotease site between Vpr and IN is necessary for
omplementation of IN mutant proviral clones (Liu et al.,
997; Fletcher et al., 1997). The release of IN from Vpr
ay be required for proper positioning within the HIV-1
ucleocapsid or the simple presence of the 96-amino-
FIG. 5. Western blotting analysis of dWF-IN and Vpr-IN import into
IV-1 virus particles. HIV-1 virions were produced and isolated as
utlined in Fig. 3 after transfection of 293T cells with (Lanes 1) pNL4-
/IN (D116N) 1 pSLX-CMV-VPR-IN or (Lanes 2) pNL4-3/IN (D116N) 1
SLX-CMV-dWF-IN. (A) Virion proteins separated in a 10–20% Tris–HCl
radient gel. (B) Virions electrophoresed through a 10–20% Tris–tricine
radient gel.
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83dWF MOTIF AND HIV-1 INTEGRASEcid Vpr at the N-terminus of IN may sterically occlude
N’s function since multimerization of the protein is re-
uired for integration activity (Jones et al., 1992; Van Gent
t al., 1993). A comparison among dWF-IN, dWF-PR-IN,
nd VPR-PR-IN using the MAGI cell assay suggests
here is not likely to be more than a twofold difference,
nd in fact they appear to be equivalent in their ability to
omplement an IN-deficient proviral clone. These results
oncur with the analysis of CAT activity imported into
IV-1 virions by fusion to Vpr or dWF (BouHamdan et al.,
998). This equivalency of activity was observed for the
omplementation of three IN-deficient proviral clones,
ne with an active-site point mutation, IN(D116N), and
wo premature termination mutants that truncate IN after
he 4th amino acid, IN(1-4), and after the 234th amino
cid, IN(1-234).
It is known that results from the MAGI cell assay can
e difficult to assess (Engelman et al., 1995). A relatively
igh background, especially of single light blue cells
ven prior to infection, and somewhat more deeply
tained cells following infection with HIV-1 in the ab-
ence of integration occurs due to some production of
ow levels of Tat from unintegrated HIV-1 DNA (Steven-
on et al., 1990). Conversely, MAGI cells passaged for a
rolonged period of time, particularly in the absence of
rowth in the appropriate selection medium, may stain
oorly despite infection and integration of HIV-1 DNA.
ue to these deficiencies, only deeply stained syncytia
ere counted to determine the relative efficiency of
omplementation among the IN chimeras and compari-
ons were made using identical batches of MAGI cells.
lthough other investigators most recently used a more
ensitive and quantitative colony-forming assay to as-
ess complementation efficiency, the use of this system
s not feasible since the proviral clones lack functional
pr (Liu et al., 1997; Fletcher et al., 1997).
Western blotting analyses to detect the incorporation
f IN chimeras within virions purified through sucrose
ushions yielded results that concur with the MAGI as-
ay complementation data. IN coupled to Vpr or dWF,
ith or without an intervening protease cleavage site,
as found to be present within HIV-1 viral particles.
lthough the Western blotting technique is not a rigorous
uantitative procedure, the analysis of virions prepared
imilarly indicated that the chimeras were incorporated
nto virions at nearly equivalent levels and certainly
ithin twofold of each other, as VPR-IN and dWF-IN
eemed to be present at levels reasonably equivalent to
N derived from the HIV-1 IN (D116N) proviral template,
hich serves as an internal standard. Virions analyzed
or the appearance of IN processed proteolytically from
ither Vpr or dWF also indicated perhaps less than two-
old reduction of IN derived from fusion with dWF versus
pr (data not shown). It seems that fusion of the 23-
mino-acid dWF motif to IN versus the larger Vpr protein
as the advantage of not having to be released from IN Dn order to catalyze the integration reaction since com-
arable levels of complementation and similar levels of
ncorporation into HIV-1 virions were observed.
Clearly, the transport of a variety of proteins into HIV-1
articles can be accomplished by direct fusion to either
pr or the Vpr interactor domain, WxxF. The use of both
ystems will likely provide the means to initiate a variety
f critical studies by allowing the direct delivery into
articles of virion-associated proteins, apart from those
ncoded by the proviral DNA. Perhaps more interesting
s the ability to assess the effect upon virion infectivity
ollowing the incorporation of protein-based molecular
herapeutics into HIV-1 virions. Such studies, though in
heir infancy, have been initiated and the results will
ikely provide new insights into lentiviral particle forma-
ion, architecture, release, and infectivity.
MATERIALS AND METHODS
lasmid construction
The HIV-1 molecular clones used include pNL4-3 and
NL4-3DVPR, obtained from the AIDS Reagent Repository,
IH, as well as HIV-1 pNL4-3, which bear the IN active-
ite point mutation, D116N, or IN termination mutants
N(1-4) and IN(1-234), kindly provided by Dr. Alan En-
elman at the Dana Farber Cancer Institute (Boston, MA).
NA fragments for insertion into pSLX-CMV-Vpr and
SLX-CMV-dWF expression vectors (BouHamdan et al.,
998) were amplified by PCR from the bacterial expres-
ion plasmid, pKK223-NY5-IN, kindly provided by Parke-
avis Pharmaceuticals Inc., using Vent polymerase (New
ngland Biolabs). The use of the IN expression cassette
rom pKK223-NY5-IN is important since the DNA se-
uences that encode IN have been changed significantly
nd are unable to recombine with the proviral-encoded
NA sequence. The 59 primers for the amplification re-
ctions contained a unique MluI site followed by se-
uences in-frame for IN or PR-IN. PR-IN incorporates
equences in the primer to append an additional 10
mino acids upstream of IN that add the natural HIV-1
rotease cleavage site at the junction between RNase H
nd IN. The sequences of the forward primers are 59-
CGCAAGCTTCGTTCCTGGACGGTATCGAT-39 (without
he protease cleavage site) and 59-CCCACGCGTTTGGT-
AGTGCTGGAATCAGGAAAGTACTATTCCTGGACGGT-39
with the protease cleavage site). The common 39 primer
or amplification of all inserts is anchored upon terminal
N sequences followed by a BglII site for insertion into
he SLX-CMV vector whose sequence is 59-GGCA-
ATCTAAGCTTTAGCTTCGTCCTG-39. All plasmids were
equenced through the inserts for their integrity prior to
se.
ell transfection and infection
Using the calcium phosphate method for delivery of
NA into cells (Profection, Promega), the human kidney
c
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84 KULKOSKY ET AL.arcinoma cell line 293T was transfected alone with
IV-1 proviral clones as indicated or cotransfected with
hese templates and SLX-CMV-VPR-IN, SLX-CMV-VPR-
R-IN, SLX-CMV-WF-IN, or SLX-CMV-dWF-PR-IN, the
uantity of which is as indicated in the figure legends.
hree days posttransfection cell supernatants containing
irus were harvested and clarified by low-speed centrif-
gation. HeLa-CD4-LTR/b-gal cells grown in either 60 3
5 or 35 3 10 mm plates were infected in duplicate at
10–15% confluency with various viral stocks. Addition
f supernatant to these MAGI reporter cells (Kimpton and
merman, 1992) was adjusted for each culture based
pon HIV-1 p24 antigen content as quantitated by ELISA
nalysis. MAGI cells contain an integrated cassette con-
isting of the the b-galactoside gene (b-gal) under the
ontrol of the HIV-1 long terminal repeat and therefore
an be stained for b-galactosidase activity typically
8–72 h postinfection as indicated in the figure legends.
he infected cells were then fixed with a solution of 0.2%
lutaraldehyde and 1% formaldehyde for 5 min at room
emperature. After fixation, the cells were washed with
hosphate-buffered saline and stained with bromo-4-
hloro-3-indolyl-b-D-galactopyranoside for 2 h at 37°C.
epresentative fields of stained cells were photographed
nd the numbers of deeply stained syncytia were deter-
ined either by visual counting through a microscope or
rom series of photographs taken in various fields of the
tained cells using an Olympus CK2 microscope.
estern blotting analyses of complemented
IV-1 virions
293T cells were grown in duplicate 100 3 20 mm
ulture dishes and transfected as described in the pre-
ious section. Virions released into the cell culture me-
ium 2.5–3 days posttransfection were centrifuged at
000 rpm for 5 min at 4°C to remove cellular debris.
fterward, virions were concentrated by adding 10 ml of
ell medium onto 2 ml of buffered, isotonic 20% sucrose
nd the cushioned medium was ultracentrifuged at
0,000 rpm for 2 h. The bulk of the solution was removed
y careful pipeting, and the pelleted virions visible as
light white pellets were removed from the bottom of the
ltracentrifuge tubes by resuspension in residual me-
ium, typically resulting in a volume of 50 to 100 ml of
oncentrated virus particles. The maximal volume of par-
icles was loaded into 10–20% Tris–HCl or Tris–tricine
recast gradient gels (Bio-Rad) and electrophoresed un-
il the bromophenol blue marker migrated to at least the
ottom of the gel. Proteins from the gel were transferred
o a Polyscreen transfer membrane using a semidry
ransfer apparatus as recommended by NEN Life Sci-
nce Products. IN or IN chimeric proteins were detected
sing a rabbit anti-IN polyclonal serum (kindly provided
y Dr. Anna Marie Skalka, Fox Chase Cancer Center,
hiladelphia, PA) and visualized by chemiluminescenceevelopment (NEN Life Science Products) of bound HRP-
onjugated anti-rabbit IgG antisera used at 1/1500 dilu-
ion (Sigma).
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